Clinical trials: Treatment Resistant Depressive Disorder
Depression, Depressive Disorder
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
To evaluate the equivalent efficacy of ultrabrief pulsewidth right unilateral electroconvulsive therapy versus bitemporal brief pulse electroconvulsive therapy in the treatment of depression and to evaluate the cognitive effects…
- Conditions
- Depression, Depressive Disorder, Treatment Resistant Depressive Disorder, Bipolar Disorder
- Trial name
- NCT02238730
- Testing
- Ultrabrief Right Unilateral, Brief Pulse Bitemporal
- Sponsor
- Kaiser Permanente
Major Depressive Disorder
Vagal Nerve Stimulation for Treatment Resistant Major Depression
The purpose of this study is to 1) explore whether vagal nerve stimulation (nVNS) using a hand- held non-invasive device (gammaCore™) works to treat depression and 2) to confirm gammaCore™'s safety profile.
- Trial name
- NCT04990687
- Testing
- gammaCore™
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Alabama at Birmingham
Depressive Disorder, Depressive Disorder, Treatment-Resistant
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
The study hypothesis is that the antidepressant effect of psilocybin is mediated by a normalization of the functioning of the positive valence system.
- Conditions
- Depressive Disorder, Depressive Disorder, Treatment-Resistant, Hallucinogens, Reinforcement, Psychology
- Trial name
- PSILODAC (NCT06650800)
- Testing
- Psilocybin, MRI
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Treatment Resistant Depression, Chronic Depression
Schema Therapy for Patients With Chronic Treatment Resistant Depression
The goal of this clinical study is to test a particular form of psychotherapy, called schema therapy, for people with difficult-to-treat depression (when depression is very lengthy or difficult to cure with antidepressive…
- Trial name
- DEPRE-ST (NCT05833087)
- Testing
- Schema therapy, Other psychotherapy, Standard care package content
- Where
- 6 sites in Denmark
- Volunteers
- 129 people
- Sponsor
- Region of Southern Denmark
Depression - Major Depressive Disorder
Chart Review of Patients Undergoing Ketamine Treatments for Depression
The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression.
- Trial name
- NCT07099235
- Testing
- ketamine hydrochloride
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Home-Based Randomized Trial of Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression
This study aims to evaluate the clinical efficacy and neurophysiological mechanisms of home-based spaced tDCS in TRD through a randomized, double-blind, sham-controlled trial conducted under remote supervision.
- Trial name
- NCT07834762
- Testing
- Spaced Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Diego
Depressive Disorder, Treatment-Resistant
Treatment-Resistant Depression Cohort in Europe
The purpose of this study is to assess the participants socio-demographics and disease-related characteristics, long-term naturalistic treatment patterns and the clinical, social and economic outcomes of routine clinical practice…
- Trial name
- NCT03373253
- Where
- 98 sites in Belgium, Germany and 5 more
- Volunteers
- 830 people
- Sponsor
- Janssen-Cilag Ltd.
Depression, Major Depressive Disorder
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours. A dose can last for a week or more. Certain receptors in the brain might help ketamine work.
- Conditions
- Depression, Major Depressive Disorder, Major Depression
- Trial name
- NCT03973268
- Testing
- Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depressive Disorder
Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.
Electroconvulsive therapy (ECT) has unparalleled efficacy in treating severe depression that is resistant to common modalities of treatment, such as antidepressant medication.
- Trial name
- NCT01748708
- Testing
- Magnetic seizure therapy, Electroconvulsive therapy
- Where
- Canada
- Sponsor
- Centre for Addiction and Mental Health
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression
The purpose of this study is to assess the impact of music on patients receiving a course of intravenous (IV) ketamine for treatment-resistant depression (TRD), both unipolar and bipolar.
- Conditions
- Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Unipolar Depression, Depression, Bipolar
- Trial name
- NCT04701866
- Testing
- Music
- Where
- 2 sites in Canada
- Volunteers
- 32 people
- Sponsor
- Douglas Mental Health University Institute
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Major Depressive Disorder
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
The purpose of this study is to see if adding the study drug, ziprasidone, to an antidepressant medication helps improve symptoms of Major Depressive Disorder (MDD).
- Trial name
- NCT00633399
- Testing
- Ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 458 people
- Sponsor
- Massachusetts General Hospital
Depression
Ketamine Plus Lithium in Treatment-Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant…
- Trial name
- NCT01880593
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms)
Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression
DECIDE- Deep phenotyping for clinical inferring response in treatment resistant depression -Study Building upon the "Biobanking" initiative at the Max Planck Institute of Psychiatry, the present project aims to identify…
- Conditions
- Depressive; Disorder, Major, Single Episode, Major, With Psychotic Symptoms, Depressive; Disorder, Major, Single Episode, Major (Without Psychotic Symptoms), Depressive Disorder, Major, Recurrent, With Psychotic Symptoms, Depressive Disorder, Major, Recurrent, Without Psychotic Symptoms
- Trial name
- DECIDE (NCT06396312)
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder
Treatment Resistant Geriatric Depression in Primary Care
This study involves collaboration between McLean Hospital, Geriatric Medicine at the Cambridge Health Alliance (CHA) and other sites within the Partners and Harvard Medical School network.
- Trial name
- NCT01392287
- Testing
- Memantine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Depressive Disorder, Major
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake…
- Trial name
- ESCAPE-TRD (NCT04338321)
- Testing
- Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg
- Where
- 171 sites in Argentina, Austria and 22 more
- Volunteers
- 676 people
- Sponsor
- Janssen-Cilag International NV
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
- Trial name
- ZYL-730-01 (NCT05323019)
- Testing
- Psychotherapy, Treatment as Usual, Intranasal Ketamine (esketamine)
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Zylorion Health
HIV, Depression in Adults
The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
The goal of this clinical trial is to learn if depression treatment improves insulin resistance, or how the body uses insulin to lower blood sugar, in people with HIV on HIV treatment.
- Conditions
- HIV, Depression in Adults, Insulin Resistance, Cognitive Behavior Therapy
- Trial name
- NCT07226128
- Testing
- Internet cognitive behavioral therapy (iCBT-D), Active Control (AC)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Indiana University
Major Depressive Disorder
Intranasal Ketamine in Treatment-Resistant Depression
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
- Trial name
- NCT01304147
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough